PharmaTimes2h
Mike Knowland
UK constumer healthcare association PAGB has appointed Bayer’s Mike Knowland as its new President. Knowland, who was ...
PharmaTimes3h
AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025
AlzeCure Pharma AB announced that its abstract on NeuroRestore ACD856 has been accepted for presentation at the AD/PD 2025 ...
PharmaTimes3h
EC approves lazertinib in combination with amivantamab for NSCLC patients
The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...
PharmaTimes1d
UK sees 70% increase in phase I advanced therapy clinical trials in 2024
The UK experienced a notable increase in advanced therapy clinical trials in 2024, reaching 187 ongoing trials. This marks a ...
PharmaTimes1d
Datapharm expands into US market through partnership with phactMI
Datapharm has announced its expansion into the United States through a new partnership with phactMI. The collaboration aims ...
PharmaTimes5d
Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials
Biofidelity and CellCarta have announced a strategic partnership to utilise Biofidelity’s Aspyre® Lung in global clinical ...
PharmaTimes5d
Actinogen boosts trial with Cambridge Cognition’s digital suite
Cambridge Cognition Holdings plc has expanded its partnership with Actinogen Medical Limited for the phase 2b/3 XanaMIA Alzheimer’s disease trial.
PharmaTimes6d
Owlstone Medical announces $27 million USD first close in Series E financing round
Owlstone Medical has announced a first close of $27 million (circa £22 million) in its Series E financing round. The round ...
PharmaTimes6d
Oxford Drug Design achieves in vivo validation for novel cancer treatment
Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its ...